Core Insights - LifeMD, Inc. has appointed Atul Kavthekar as Chief Financial Officer to support its growth phase, with Marc Benathen departing to pursue new opportunities [1][2][6] Leadership Changes - Atul Kavthekar brings nearly three decades of experience in healthcare and technology, focusing on financial infrastructure and operational performance [2][3] - Chris Pisano has been appointed as Chief Marketing Officer, bringing over 25 years of marketing experience to enhance brand strategy and market positioning [4][6] - Jessica Friedeman will assume the role of Chief Business Officer, focusing on enterprise and employer health offerings while continuing her leadership in women's health [5][6] Strategic Focus - Kavthekar will work with the technology team to position LifeMD as an AI-first healthcare company, aiming to improve patient access and clinical outcomes [3][4] - The leadership changes are designed to leverage the strengths of the management team as LifeMD enters a new growth phase [6] Employment Inducement Grant - As part of his employment, Kavthekar will receive 675,000 restricted stock units, with vesting conditions based on service and performance targets [7] Company Overview - LifeMD is a leading provider of virtual primary care services, offering telemedicine and specialized treatment across over 200 conditions [8]

Core Insights - LifeMD, Inc. has been recognized on the 2025 Deloitte Technology Fast 500™ and TIME's inaugural America's Growth Leaders of 2026 lists, highlighting its revenue growth and leadership in the health technology sector [1][4] Company Performance - LifeMD's integrated telehealth platform has successfully addressed the rising demand for accessible virtual healthcare, particularly in high-growth markets such as weight management, mental health, and hormone replacement therapy [2][3] - The company has made significant investments in its enterprise platform, including a state-of-the-art compounding pharmacy and expanded insurance coverage, which have contributed to its growth [3] Industry Recognition - The Deloitte Technology Fast 500 ranks the fastest-growing technology companies in North America based on revenue growth from 2021 to 2024, with LifeMD being recognized for its exceptional performance [5][6] - TIME's America's Growth Leaders of 2026 list identifies companies based on five-year growth performance, financial health, and stock performance, further solidifying LifeMD's position among dynamic U.S. companies [8]

Group 1 - A class action has been filed against LifeMD, Inc. (NASDAQ: LFMD) on behalf of investors who acquired its securities between May 7, 2025, and August 5, 2025 [1][2] - The allegations include that LifeMD misled investors about its competitive position and failed to properly account for rising customer acquisition costs, particularly in its RexMD segment and for obesity treatment drugs [2] - Following the announcement of its second quarter 2025 results and a revision of its full-year guidance, LifeMD's stock price dropped by $5.31, or 44.8%, closing at $6.53 on August 6, 2025 [3] Group 2 - Shareholders interested in serving as lead plaintiffs must file their papers with the court by October 27, 2025, and can choose to remain absent class members if they do not wish to participate [4] - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses for representation [5]